Medicare Enrolled
Dr. Matthew Truesdale, M.D.
Urology Physician · Largo, FL
Practice pattern: Clinical Cardiology— Primarily office-based clinical cardiology
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Truesdale from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Truesdale? Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Truesdale
Dr. Matthew Truesdale is an urology physician in Largo, FL, with 14 years in practice. Based on federal Medicare data, Dr. Truesdale performed 5,951 Medicare services across 3,726 unique beneficiaries.
Between the years covered by Open Payments, Dr. Truesdale received a total of $8,683 from 59 pharmaceutical and/or device companies across 256 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in urology physician. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Truesdale is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 14 years in practice▲ Top 21% volume in FL$ $8,683 industry payments
Medicare Practice Summary
Medicare Utilization ↗5,951
Medicare services
Top 21% in FL for urology physician
3,726
Unique beneficiaries
$59
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~425 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Automated urinalysis | 1,394 | $2 | $5 |
| Office visit, established patient (30-39 min) | 1,022 | $92 | $321 |
| Office visit, established patient (20-29 min) | 715 | $69 | $227 |
| Bladder ultrasound after voiding | 281 | $8 | $26 |
| New patient office visit (45-59 min) | 173 | $118 | $422 |
| Insertion of implant in urethra within prostate gland using an endoscope, each additional implant | 170 | $41 | $130 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 166 | $136 | $368 |
| Diagnostic exam of bladder and urethra using an endoscope | 158 | $180 | $603 |
| Blood draw (venipuncture) | 156 | $6 | $6 |
| Hospital follow-up visit, low complexity | 128 | $41 | $98 |
| Chronic care management, first 20 min/month | 127 | $50 | $159 |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 120 | $30 | $161 |
| Ceftriaxone antibiotic injection | 117 | $0 | $1 |
| Insertion of lower leg neurostimulator electrode | 116 | $90 | $302 |
| Limited ultrasound scan behind abdominal cavity | 93 | $34 | $116 |
| Electronic assessment of bladder emptying | 87 | $6 | $36 |
| Complete ultrasound scan of pelvis | 87 | $80 | $211 |
| Instillation of anti-cancer drug into bladder | 81 | $68 | $220 |
| Complex measurement of pressure of urine flow in bladder with urethra pressure and voiding pressure studies | 71 | $295 | $949 |
| Insertion of device into abdomen with pressure and urine flow rate study | 71 | $145 | $467 |
| Drug injection, under skin or into muscle | 60 | $11 | $35 |
| Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | 50 | $18 | $57 |
| Initial hospital care with straightforward or low level of medical decision making, per day, if using time, at least 40 minutes | 45 | $67 | $256 |
| Initial hospital admission, moderate complexity | 41 | $106 | $341 |
| Insertion of implant in urethra within prostate gland using an endoscope, 1 implant | 40 | $163 | $536 |
| Ultrasound scan of pelvic region through rectum | 40 | $103 | $327 |
| New patient office visit (30-44 min) | 38 | $84 | $283 |
| Insertion of stent in ureter using an endoscope | 36 | $86 | $396 |
| Other procedure on male genital system | 34 | $134 | $1,000 |
| Application of electrical stimulation with therapist present, each 15 minutes | 32 | $11 | $37 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 31 | $26 | $81 |
| Test or measurement for functional capacity, each 15 minutes | 31 | $27 | $84 |
| Crushing of stone of ureter with insertion of stent using an endoscope | 27 | $329 | $1,063 |
| Biopsy of prostate gland | 24 | $193 | $617 |
| Hospital follow-up visit, moderate complexity | 20 | $64 | $179 |
| Telephone medical discussion with physician, 5-10 minutes | 20 | $28 | $114 |
| Simple insertion of temporary bladder tube | 17 | $49 | $156 |
| Injection, garamycin, gentamicin, up to 80 mg | 17 | $2 | $3 |
| Electronic analysis of implanted neurostimulator generator with complex spinal cord or peripheral nerve stimulator programming | 15 | $46 | $142 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
1.1% high complexity
12.6% medium
86.3% routine
Industry Payment Transparency
Open Payments through 2024 ↗$8,683
Total received (2018-2024)
Avg $1,240/year across 7 years
Top 23% in FL for urology physician
59
Companies
256
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$5,060 (58.3%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$3,500 (40.3%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$122 (1.4%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024$4,705
2023$1,407
2022$1,248
2021$400
2020$150
2019$365
2018$408
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Janssen Biotech, Inc.
$3,748
Dendreon Pharmaceuticals LLC
$478
Sumitomo Pharma America, Inc.
$391
Endo Pharmaceuticals Inc.
$371
Astellas Pharma US Inc
$295
Myriad Genetic Laboratories, Inc.
$229
PFIZER INC.
$223
ABBVIE INC.
$216
Merck Sharp & Dohme LLC
$201
Teleflex LLC
$196
Boston Scientific Corporation
$167
AbbVie Inc.
$156
Astellas Pharma Global Development
$125
Bayer Healthcare Pharmaceuticals Inc.
$117
UroGen Pharma, Inc.
$114
Amgen Inc.
$110
Novartis Pharmaceuticals Corporation
$94
AstraZeneca Pharmaceuticals LP
$93
Myovant Sciences Inc.
$85
UROVANT SCIENCES INC
$85
Laborie Medical Technologies Corp.
$75
Bayer HealthCare Pharmaceuticals Inc.
$73
Antares Pharma, Inc.
$67
BOSTON SCIENTIFIC CORPORATION
$66
Endo USA, Inc.
$57
Avadel Specialty Pharmaceuticals, LLC
$50
Progenics Pharmaceuticals, Inc.
$47
Ferring Pharmaceuticals Inc.
$44
UROGEN PHARMA, INC.
$43
Coloplast Corp
$41
Blue Earth Diagnostics Limited
$41
Rochester Medical Corporation
$41
TOLMAR Pharmaceuticals, Inc.
$38
Axonics, Inc.
$38
PROGENICS PHARMACEUTICALS, INC.
$38
Acerus Pharmaceuticals Corporation
$33
Baxter Healthcare
$26
Clarus Therapeutics Inc.
$26
Merck Sharp & Dohme Corporation
$23
Tolmar, Inc.
$23
Telix Pharmaceuticals
$22
Metuchen Pharmaceuticals
$21
COLOPLAST CORP
$21
ACCORD HEALTHCARE, INC.
$20
Medtronic, Inc.
$20
Calyxo, Inc.
$20
Covidien LP
$16
IMMUNITYBIO, INC.
$16
Olympus America Inc.
$16
KARL STORZ Endoscopy-America
$15
Travere Therapeutics, Inc.
$14
TherapeuticsMD, Inc.
$14
Retrophin, Inc.
$13
MEDIVATION FIELD SOLUTIONS LLC
$13
Allergan, Inc.
$13
AbbVie, Inc.
$13
AngioDynamics, Inc.
$12
Mission Pharmacal Company
$11
Ambu Inc.
$10
Top 3 companies account for 53.2% of total payments
Associated products mentioned in payments ›
(815) Thiola · 16 FR. FLEXIBLE VIDEO CYSTOSCOPE · ADSTILADRIN · AMS 700 CXR RTE KIT · ANKTIVA · AVEED · Axonics · Axumin · BOTOX · BRAC CDx · Bulkamid · CAMCEVI · CVAC ASPIRATION SYSTEM · EDEX · ELIGARD · ERLEADA · Erleada · GEMTESA · ILLUCCIX · IMVEXXY · JATENZO · JELMYTO · KEYTRUDA · LITHOVUE · LUPRON DEPOT · LYNPARZA · Lapro-Clip · LithoVue · Lupron · MYRBETRIQ · Myrbetriq · NANOKNIFE · Natesto · Noctiva · Nubeqa · ORGOVYX · Optilume BPH Drug Coated Balloon Catheter · PLUVICTO · POSLUMA · PROLARIS · PROVENGE · PYLARIFY · Padcev · Prolaris · RESTORELLE · SONICISION · SpeediCath · Stendra · TISSEEL · Thiola · UROLIFT · Uribel · XGEVA · XIAFLEX · XTANDI · XYOSTED · Xtandi · ZYTIGA · iTIND System
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (58%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Equivalent to $146 per 100 Medicare services performed
Geographic Context
Urology Physicians within 10 mi
102
Per 100K population
10.6
County median income
$70,293
Nearest hospital
WINDMOOR HEALTHCARE OF CLEARWATER
2.4 mi
2.4 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Truesdale is a clinical cardiology specialist, with above-average Medicare volume (top 21% in FL), and low-engagement industry engagement.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Truesdale experienced with automated urinalysis?
Based on Medicare claims data, Dr. Truesdale performed 1,394 automated urinalysis services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Truesdale receive payments from pharmaceutical companies?
Yes. Dr. Truesdale received a total of $8,683 from 59 companies across 256 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Truesdale's costs compare to other urology physicians in Largo?
Dr. Truesdale's average Medicare payment per service is $59. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Truesdale) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Urology Physicians in Largo
Browse urology physicians in Largo ranked by procedure volume and transparency data.
Highest volume
Top Urology Physicians in FL
Urology Physicians ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Urology Physicians in FL
Which FL urology physicians receive the most from drug and device companies.
By company
Janssen Biotech, Inc. Payments to Doctors
See all physicians who received payments from Janssen Biotech, Inc..
By company
Dendreon Pharmaceuticals LLC Payments to Doctors
See all physicians who received payments from Dendreon Pharmaceuticals LLC.
By company
Sumitomo Pharma America, Inc. Payments to Doctors
See all physicians who received payments from Sumitomo Pharma America, Inc..
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology